WAS and Wiskott-Aldrich syndrome: Ferrua et al. presented safety and efficacy data from an interim analysis of a phase 1/2 clinical study on patients with severe WAS who underwent lentiviral vector-based gene therapy.370 The treatment involved a single intravenous infusion of autologous CD34+ cells genetically modified with a lentiviral vector encoding human WAS cDNA.